Catalyst Pharmaceuticals posted on its website a response to the February 4 letter that the company received from Senator Bernie Sanders. Catalyst says it “respectfully question(s)” the notion that an experimental product that hasn’t received FDA approval is an acceptable standard of care for the Lambert-Eaton myasthenic syndrome patients treated by Firdapse. Further, Catalyst believes its pricing of Firdapse is “in line with the pricing of other products that provide significant clinical benefits in treating an ultra-orphan disease of similar severity.”